GT Biopharma, Inc.
GTBPNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $0 |
| Operating income | −$3.4M | −$14.4M | −$13.6M | −$21.3M | −$57.5M | $6.8M |
| Net income | −$30.9M | −$13.2M | −$7.6M | −$20.9M | −$58.0M | −$19.1M |
| Total assets | $7.1M | $4.2M | $14.1M | $16.7M | $32.2M | $5.7M |
| Total liabilities | $31.0M | — | $6.6M | $5.0M | $10.3M | — |
| Equity | −$25.9M | −$1.7M | $7.5M | $11.7M | $21.9M | −$27.5M |
| EPS (diluted) | $-12.12 | $-6.94 | $-5.64 | $-19.66 | $-2.06 | — |
| Shares out. | 2.2M | 1.4M | 36.8M | 32.1M | 28.4M | 70.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- 119.6%
- Return on assets
- −434.4%
- Return on capital (ROCE)
- −71.7%
- Liabilities / assets
- 435.8%
- Debt / equity
- —
- Book value / share
- $-11.58
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -331.14distress
- Accruals / assets
- −361.2%clean
- Piotroski F-Score
- 2/6weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 2 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Aug 17, 2021
- NT 10-Kmissed a reporting deadline ↗Mar 31, 2021
- NT 10-Kmissed a reporting deadline ↗Apr 1, 2013
- NT 10-Qmissed a reporting deadline ↗Nov 15, 2012
- NT 10-Qmissed a reporting deadline ↗Aug 14, 2012
- NT 10-Qmissed a reporting deadline ↗May 15, 2012
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Bristol Investment Fund LtdPassive (13G)Jun 2, 2025
- Five Narrow Lane LpPassive (13G)May 14, 2025
- Cytovance Biologics IncPassive (13G)Oct 17, 2024
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 2.1M | 1.0 | +243.3% |
| Apr 30, 2026 | 604,557 | 1.0 | -9.9% |
| Apr 15, 2026 | 671,073 | 1.3 | -10.2% |
| Mar 31, 2026 | 747,375 | 1.1 | -26.7% |
| Mar 13, 2026 | 1.0M | 1.4 | -51.2% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Delisting / listing-standard noticeMay 22, 2026
- Entered a material agreementApr 7, 2026
- Prior financials not reliable (restatement)Mar 2, 2026
- Delisting / listing-standard noticeNov 26, 2025
- Results of operationsNov 14, 2025
- Modified shareholder rightsSep 26, 2025
- Modified shareholder rightsSep 23, 2025
- Director / officer changeAug 29, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.